- Home
- GFAI vs CANF Comparison
GFAI vs CANF Comparison
Compare GFAI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFAI
- CANF
- Stock Information
- Founded
- GFAI 2018
- CANF 1994
- Country
- GFAI Singapore
- CANF Israel
- Employees
- GFAI N/A
- CANF N/A
- Industry
- GFAI Diversified Commercial Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- GFAI Consumer Discretionary
- CANF Health Care
- Exchange
- GFAI Nasdaq
- CANF Nasdaq
- Market Cap
- GFAI 12.5M
- CANF 14.4M
- IPO Year
- GFAI N/A
- CANF N/A
- Fundamental
- Price
- GFAI $1.09
- CANF $2.01
- Analyst Decision
- GFAI Strong Buy
- CANF Strong Buy
- Analyst Count
- GFAI 2
- CANF 2
- Target Price
- GFAI $6.75
- CANF $14.00
- AVG Volume (30 Days)
- GFAI 195.4K
- CANF 63.2K
- Earning Date
- GFAI 11-29-2024
- CANF 11-26-2024
- Dividend Yield
- GFAI N/A
- CANF N/A
- EPS Growth
- GFAI N/A
- CANF N/A
- EPS
- GFAI N/A
- CANF N/A
- Revenue
- GFAI $35,841,743.00
- CANF $667,000.00
- Revenue This Year
- GFAI $0.37
- CANF $409.56
- Revenue Next Year
- GFAI $5.60
- CANF N/A
- P/E Ratio
- GFAI N/A
- CANF N/A
- Revenue Growth
- GFAI 1.78
- CANF N/A
- 52 Week Low
- GFAI $1.00
- CANF $1.87
- 52 Week High
- GFAI $4.30
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- GFAI 46.86
- CANF 38.15
- Support Level
- GFAI $1.02
- CANF $1.93
- Resistance Level
- GFAI $1.13
- CANF $2.21
- Average True Range (ATR)
- GFAI 0.07
- CANF 0.20
- MACD
- GFAI 0.00
- CANF -0.02
- Stochastic Oscillator
- GFAI 56.25
- CANF 15.52
About GFAI Guardforce AI Co. Limited
Guardforce AI Co Ltd is a provider of cash solutions and cash handling services located in Thailand. The company engages in the cash logistics business, and its services include cash-in-transit, or CIT, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions (cash deposit management and express cash service). Its customers include local commercial banks, chain retailers, coin-manufacturing mints, and government authorities.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).